About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
Myeloproliferative Neoplasms (MPNs): Post-ASH 2017 Wrap Up and Future Directions Discussion
By
Naveen Pemmaraju
12 Videos
128 views
March 5, 2018
0 Comments
Login to view comments.
Click here to Login
Featured Video
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Related Content
AUTOPLAY
ON
19:49
Rush University Medical Center
COVID-19 Coagulopathy: Whom to Anticoagulate and How? What Agents to…
Feat.
S. Jain
18:41
CHEST 2022 Coverage
Role of Anticoagulants and Antiplatelet Agents for Patients With COV…
Feat.
V. Balasubramanian
21:20
Cleveland Clinic Rheumatology
How do I Recognize and Treat the VEXAS Syndrome?
Feat.
P. Grayson
31:18
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2023
Thrombosis and Anticoagulation: 2023 Update
Feat.
S. Moll
27:37
Indy Hematology Review
Review of Myeloproliferative Neoplasms
Feat.
A. Tefferi
18:04
Ruben Mesa
Momelotinib for Myelofibrosis: Top 10 Things You Should Know Post-FD…
08:18
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Treatment Strategies for Hematocrit Control…
Feat.
A. Zhou
05:20
Prithviraj Bose
When to Switch From Hydroxyurea to Ruxolitinib in PV
31:43
Indy Hematology Review
Myelofibrosis: Chronic and Blast Phase - 2023 Algorithms for Risk St…
Feat.
A. Tefferi
21:52
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "MF, ET, and PV - Highlights and Clinical Imp…
Feat.
D. Tremblay
10:02
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "The Best of MPNs - Highlights & Key Take…
Feat.
R. Mesa
09:27
ASH 2022 Conference Coverage
MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…
Feat.
M. McMullin
28:10
Indy Hematology Review
Current Review of Benign Hematology and Coagulopathy
Feat.
C. Kessler
12:18
Fred Hutchinson Cancer Center
Management of MPNs for the Community Oncologist
Feat.
H. Deeg
12:07
Douglas Tremblay
Monitoring Patients With MF: When to Switch Treatment
16:25
Northwestern Medicine Oncology and Hematology
Diagnosis and Goals of Therapy in PV
Feat.
B. Stein
13:36
Vanderbilt University Medical Center (VUMC)
Venous Thromboembolism Prophylaxis in Newly Diagnosed MM
Feat.
M. Baljevic
28:59
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2024
Management of Simultaneous Venous and Arterial Thromboembolic Disease
Feat.
J. May
09:46
Scripps MD Anderson Cancer Center
Ruxolitinib in Polycythemia Vera: Learnings From the RESPONSE Trial
Feat.
D. Hermel
08:44
Krisstina Gowin
Management of Aquagenic Pruritis in Polycythemia Vera
